Merrion Pharmaceuticals Plc.

Type 2 diabetes isn’t an obvious spot for any aspiring biotech entrepreneur to invest hard-raised dollars. The highly competitive marketplace is dominated by Sanofi , desperate as $7 billion Lantu

As an industry, biopharma actually fares pretty well when it comes to taxes. Among profitable companies, biotech and pharma have some of the lowest effective U.S. tax rates compared to companies in ot

Novo Nordisk AS is betting that the latest generation of insulin, GLP-1 agonists, as well as combinations thereof will be enough to drive the company forward through the end of this decade. But majo

While most drug delivery deal-making traditionally revolves around products that have been launched or specialty products to extend and protect a product's market position, a new study from the Indian